CS 917

Drug Profile

CS 917

Alternative Names: CS-917; MB 6322; MB06322

Latest Information Update: 23 Jan 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Metabasis Therapeutics
  • Developer Daiichi Sankyo Inc; Metabasis Therapeutics
  • Class Amino acids; Antihyperglycaemics; Organophosphorus compounds; Small molecules
  • Mechanism of Action Fructose bisphosphatase inhibitors; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 29 Jun 2007 Data presented at the 67th Scientific Sessions of the American Diabetes Association (ADA-2007) added to the Diabetes pharmacodynamics section
  • 26 Jun 2007 Daiichi Sankyo completes a phase IIb trial in Diabetes in the US
  • 01 Feb 2007 Daiichi Sankyo completes enrolment in its phase IIb trial for Type-2 diabetes in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top